SuperworthBiodesix BDSX
- Market cap
- $223.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.2×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $102.9M
- +34% on a year ago
- Net margin
- −27.0%
- Free cash flow yield
- −9.1%
Biodesix trades at 2.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $102.9M over the last twelve months, up 34% on a year earlier with a −27% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $13.5M+22% | $14.7M+53% | $14.8M+64% | $17.9M+51% | $18.2M+35% | $20.4M+39% | $18M+21% | $20M+12% | $21.8M+20% | $28.8M+41% | $25.6M+42% | $26.9M+34% | |
| R&D | $1.9M−35% | $1.9M−47% | $2M−37% | $2.6M−12% | $2.5M+31% | $2.4M+28% | $2.9M+41% | $3.3M+28% | $3M+18% | $2.9M+19% | $3.3M+15% | $3.1M−4% |
| SG&A | $15.5M+3% | $16.3M−2% | $20.6M+8% | $19.7M+18% | $20M+29% | $20.2M+24% | $20.4M−1% | $22.4M+14% | $21.7M+9% | $23M+14% | $24.3M+19% | $24.3M+8% |
| −$7.2M−32% | −$6.9M−51% | −$11M−33% | −$8.2M−25% | −$8.6M+20% | −$6.6M−3% | −$9.1M−17% | −$9.7M+18% | −$7.1M−18% | −$2M−70% | −$6.2M−32% | −$5.4M−45% | |
| Interest expense | $2.4M−22% | $2.3M−9% | $2.5M+6% | $1.9M−20% | $2M−15% | $1.8M−25% | $1.7M−33% | $1.9M−2% | $2.1M+2% | $2.1M+18% | $2M+17% | $2M+4% |
| Net income | −$10.9M−20% | −$9.1M−55% | −$13.6M−27% | −$10.8M−19% | −$10.3M−6% | −$8.3M−10% | −$11.1M−19% | −$11.5M+6% | −$8.7M−15% | −$4M−52% | −$7.8M−30% | −$7.3M−37% |
| −$2.80−59% | −$2.00−71% | −$2.80−42% | −$1.60−53% | −$1.40−50% | −$1.13−44% | −$1.52−46% | −$1.56−3% | −$1.16−17% | −$0.49−57% | −$0.81−47% | −$0.71−55% | |
| 4M+97% | 4.6M+61% | 4.9M+25% | 6.4M+62% | 7.3M+84% | 7.3M+59% | 7.3M+50% | 7.3M+15% | 7.5M+3% | 8.1M+10% | 9.7M+32% | 10.3M+40% |
EPS, diluted: 6 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Biodesix's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BDSXBiodesix | $223.5M | n/m | n/a | 2.2× | +34% | −27.0% | |
| ELMDElectromed | $220.6M | 20.1× | 29.0× | 3.0× | +15% | 15.3% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| VMDViemed Healthcare | $373.3M | 27.2× | 26.1× | 1.2× | +25% | 4.8% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| NRCNRC Health | $485.1M | 87.7× | 35.1× | 3.5× | −0% | 4.2% | |
| Peer median | $257M | 21.4× | 27.6× | 2.2× | +5% | 7.3% |
More on Biodesix
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .